Patents by Inventor Daniel F. Veber
Daniel F. Veber has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 7563784Abstract: The present invention provides C1-6alkyl-4-amino-azepan-3-one protease inhibitors and pharmaceutically acceptable salts, hydrates and solvates thereof which inhibit proteases, including cathepsin K, pharmaceutical compositions of such compounds, novel intermediates of such compounds, and methods for treating diseases of excessive bone loss or cartilage or matrix degradation, including osteoporosis; gingival disease including gingivitis and periodontitis; arthritis, more specifically, osteoarthritis and rheumatoid arthritis; Paget's disease; hypercalcemia of malignancy; and metabolic bone disease; and parasitic diseases, including malaria, by administering to a patient in need thereof one or more compounds of the present invention.Type: GrantFiled: April 25, 2006Date of Patent: July 21, 2009Assignee: SmithKline Beecham CorporationInventors: Maxwell D. Cummings, Robert W. Marquis, Jr., Yu Ru, Scott K. Thompson, Daniel F. Veber, Dennis S. Yamashita
-
Patent number: 7071184Abstract: The present invention provides C1-6alkyl-4-amino-azepan-3-one protease inhibitors and pharmaceutically acceptable salts, hydrates and solvates thereof which inhibit proteases, including cathepsin K, pharmaceutical compositions of such compounds, novel intermediates of such compounds, and methods for treating diseases of excessive bone loss or cartilage or matrix degradation, including osteoporosis; gingival disease including gingivitis and periodontitis; arthritis, more specifically, osteoarthritis and rheumatoid arthritis; Paget's disease; hypercalcemia of malignancy; and metabolic bone disease; and parasitic diseases, including malaria, by administering to a patient in need thereof one or more compounds of the present invention.Type: GrantFiled: March 7, 2001Date of Patent: July 4, 2006Assignee: SmithKline Beecham CorporationInventors: Maxwell D. Cummings, Robert W. Marquis, Jr., Daniel F. Veber, Dennis S. Yamashita
-
Publication number: 20040229863Abstract: The present invention provides methods which use 4-amino-azepan-3-one protease inhibitors of cathepsin S in the treatment of diseases in which cathepsin S is implicated, especially treatment or prevention of autoimmune disease; treatment or prevention of a disease state caused by the formation of atherosclerotic lesions and complications arising therefrom; and diseases requiring inhibition, for therapy, of a class II MHC-restricted immune response, inhibition of an asthmatic response, inhibition of an allergic response, inhibition of immune response against a transplanted organ or tissue, or inhibition of elastase activity in atheroma, and novel compounds for use therewith.Type: ApplicationFiled: March 10, 2004Publication date: November 18, 2004Applicant: SmithKline Beecham CorporationInventors: Maxwell D. Cummings, Robert W. Marquis, Yu Ru, Scott K. Thompson, Daniel F. Veber, Dennis S. Yamashita
-
Publication number: 20040180927Abstract: The present invention relates to compounds of formula (I): 1Type: ApplicationFiled: February 27, 2004Publication date: September 16, 2004Applicant: SmithKline Beecham CorporationInventors: Robert W. Marquis, Daniel F. Veber, Yu Ru, Stephen Lo Castro
-
Publication number: 20040044201Abstract: The present invention provides C1-6alkyl-4-amino-azepan-3-one protease inhibitors and pharmaceutically acceptable salts, hydrates and solvates thereof which inhibit proteases, including cathepsin K, pharmaceutical compositions of such compounds, novel intermediates of such compounds, and methods for treating diseases of excessive bone loss or cartilage or matrix degradation, including osteoporosis; gingival disease including gingivitis and periodontitis; arthritis, more specifically, osteoarthritis and rheumatoid arthritis; Paget's disease; hypercalcemia of malignancy; and metabolic bone disease; and parasitic diseases, including malaria, by administering to a patient in need thereof one or more compounds of the present invention.Type: ApplicationFiled: September 20, 2002Publication date: March 4, 2004Inventors: Maxwell D. Cummings, Robert W. Marquis Jr., Yu Ru, Scott K. Thompson, Daniel F. Veber, Dennis S. Yamashita
-
Publication number: 20040038965Abstract: The present invention provides C3-C6 1-amino-1-acyl cycloalkane-substituted 4-amino-azepan-3-one protease inhibitors and pharmaceutically acceptable salts, hydrates and solvates thereof which inhibit proteases, including cathepsin K, pharmaceutical compositions of such compounds, novel intermediates of such compounds, and methods for treating diseases of excessive bone loss or cartilage or matrix degradation, including osteoporosis; gingival disease including gingivitis and periodontitis; arthritis, more specifically, osteoarthritis and rheumatoid arthritis; Paget's disease; hypercalcemia of malignancy; and metabolic bone disease, comprising inhibiting said bone loss or excessive cartilage or matrix degradation by administering to a patient in need thereof a compound of the present invention.Type: ApplicationFiled: May 22, 2003Publication date: February 26, 2004Inventors: Robert W. Marquis, Jr., Daniel F. Veber, Dennis S. Yamashita
-
Publication number: 20040034013Abstract: The present invention provides methods which use 4-amino-azepan-3-one protease inhibitors of cathepsin L in the treatment of diseases in which cathepsin L is implicated, especially treatment or prevention of rheumatoid arthritis; treatment or prevention of cancer metastasis; treatment or prevention of diseases requiring inhibition of tissue destruction by macrophage, particularly lung macrophage, such as asthma, chronic obstructive pulmonary disease (COPD), and emphysema; treatment or prevention of diseases requiring, for therapy, inhibition of positive selection of CD4+ T-cells by cortical thymic epithelial cells.Type: ApplicationFiled: October 17, 2002Publication date: February 19, 2004Inventors: Maxwell D Cummings, Robert W Marquis, Yu Ru, Scott K Thompson, Daniel F Veber, Dennis S Yamashita
-
Publication number: 20030114437Abstract: The present invention provides methods which use 4-amino-azepan-3-one protease inhibitors of cathepsin S in the treatment of diseases in which cathepsin S is implicated, especially treatment or prevention of autoimmune disease; treatment or prevention of a disease state caused by the formation of atherosclerotic lesions and complications arising therefrom; and diseases requiring inhibition, for therapy, of a class II MHC-restricted immune response, inhibition of an asthmatic response, inhibition of an allergic response, inhibition of immune response against a transplanted organ or tissue, or inhibition of elastase activity in atheroma, and novel compounds for use therewith.Type: ApplicationFiled: October 17, 2002Publication date: June 19, 2003Inventors: Maxwell D. Cummings, Robert W. Marquis Jr, Yu Ru, Scott K. Thompson, Daniel F. Veber, Dennis S. Yamashita
-
Publication number: 20030096760Abstract: Invented is a method of treating a bone resorption disease in a subject which comprises administering to the subject a therapeutically effective amount of a compound which forms a covalent bond or link to cys 185 of the src SH2 domain.Type: ApplicationFiled: April 8, 2002Publication date: May 22, 2003Applicant: SmithKlineBeecham CorporationInventors: Dennis S. Yamashita, Daniel F. Veber, Dennis A. Holt
-
Patent number: 6566373Abstract: The invention relates to 3-hydroxy-and 3-keto-cyclohetero-substituted leucine compounds that are inhibitors of cysteine proteases, particularly cathepsin K, and are useful in the treatment of diseases in which inhibition of bone loss is a factor. The 3-hydroxy-or 3-keto-moiety is bonded to a tetrahydrothiophene, tetrahydrothiopyran, tetrahydrofuran or tetrahydropyran ring.Type: GrantFiled: July 30, 2001Date of Patent: May 20, 2003Assignees: SmithKline Beecham Corporation, SmithKline Beecham p.l.c.Inventors: Andrew D Gribble, Ashley Edward Fenwick, Robert W Marquis, Daniel F Veber, Jason Witherington
-
Publication number: 20020128476Abstract: This invention relates to compounds of formula (I): 1Type: ApplicationFiled: April 17, 2001Publication date: September 12, 2002Applicant: SmithKline Beecham corporationInventors: Robert W. Marquis, Daniel F. Veber, Yu Ru, Stephen Lo Castro
-
Patent number: 6369077Abstract: This invention relates to compounds of formula (I): wherein: Y is Ar or NR1R2; R1 is R″, R″C(O), R″C(S), R″SO2, R″OC(O), R″R′NC(O), or R″R′NC(S); R2 is H, C1-6alkyl, C2-6alkenyl, Ar-C0-6alkyl, or Het-C0-6alkyl; R3 is H, C2-6alkenyl, C2-6alkynyl, Het, Ar or C1-6alkyl optionally substituted by OR′, SR′, NR′2, N(R′)C(O)OR″, CO2R′, CO2NR′2, N(C═NH)NH2, Het or Ar; R4 is H, C1-6alkyl, C2-6alkenyl, Ar-C0-6alkyl, or Het-C0-6alkyl; R5 is Ar-C0-6alkyl, Het-C0-6alkyl, adamantyl-C(O)—, Ar-C(O)—, Het-C(O)— or; R6 is R″, R″C(O), R″C(S), R″SO2, R″OC(O), R″R′NC(O), R″R′NC(S), or R″OC(O)NR′CH(R*)C(O); R7 is C3-6cycloalkyl-C0-6alkyl, Ar-C0-6alkyl, Het-C0-6alkyl, Ar-C0-6alkoxy, Het-C0-6alkoxy, or C1-6alkyl optionally substituted by OR′, SR′, NR′2, N(R′)C(O)OR″, CO2R&pType: GrantFiled: November 4, 1999Date of Patent: April 9, 2002Assignee: SmithKline Beecham CorporationInventors: Robert W. Marquis, Yu Ru, Daniel F. Veber, Stephen M. LoCastro
-
Publication number: 20020013360Abstract: The invention relates to 3-hydroxy-and 3-keto-cyclohetero-substituted leucine compounds that are inhibitors of cysteine proteases, particularly cathepsin K, and are useful in the treatment of diseases in which inhibition of bone loss is a factor. The 3-hydroxy-or 3-keto-moiety is bonded to a tetrahydrothiophene, tetrahydrothiopyran, tetrahydrofuran or tetrahydropyran ring.Type: ApplicationFiled: July 30, 2001Publication date: January 31, 2002Applicant: SmithKline Beecham CorporationInventors: Andrew D. Gribble, Ashley Edward Fenwick, Robert W. Marquis, Daniel F. Veber, Jason Witherington
-
Patent number: 5693643Abstract: Compounds of formula (I) wherein X is (a) or (b), R is Het as defined in the description. These compounds are oxytocin and vasopressin antagonists useful in the treatment of preterm labor, dysmenorrhea, and for the stoppage of labor preparatory to Cesarean delivery.Type: GrantFiled: August 15, 1995Date of Patent: December 2, 1997Assignee: Merck & Co., Inc.Inventors: Kevin Gilbert, Peter D. Williams, Ben E. Evans, Doug W. Hobbs, Daniel F. Veber
-
Patent number: 5681926Abstract: Peptides having the general sequence A-B-C-D-E-F-Z wherein A is Ala, B is pFPhe, C is, for example, Arg, D is Cha, E is, for example, hArg, F is, for example, Tyr, and Z is, for example NH.sub.2. The peptides are useful for promoting wound healing and arresting bleeding in a patient.Type: GrantFiled: December 15, 1995Date of Patent: October 28, 1997Assignee: Merck & Co., Inc.Inventors: Daniel F. Veber, Ruth F. Nutt, Dong-Mei Feng, Robert J. Gould, Thomas M. Connolly
-
Patent number: 5672582Abstract: 4-substituted cyclohexylamine derivatives which are thrombin catalytic site inhibitors and which are useful as anticoagulants. These compounds show selectivity for thrombin over other trypsin-like enzymes and have oral bioavailability.Type: GrantFiled: October 12, 1994Date of Patent: September 30, 1997Assignee: Merck & Co., Inc.Inventors: Daniel F. Veber, S. Dale Lewis, Jules A. Shafer, Dong-Mei Feng, Ruth F. Nutt, Stephen F. Brady
-
Patent number: 5648352Abstract: The invention is directed to a series of novel piperazinylcamphorsulfonyl compounds where the camphor ring is substituted by amides, amines, alkanes, alkenes, alkylamines, halogens, hydroxy, carboxy, alkoxycarbonyl and heterocyclic tings. Such compounds are oxytocin antagonists useful in the treatment of preterm labor, dysmenorrhea and for the stoppage of labor preparatory to cesarean delivery.Type: GrantFiled: May 26, 1995Date of Patent: July 15, 1997Assignee: Merck & Co., Inc.Inventors: Mark G. Bock, Jill M. Erb, Doug W. Hobbs, James B. Hoffman, Joseph M. Pawluczyk, Debra S. Perlow, Daniel F. Veber, Peter D. Williams
-
Patent number: 5492917Abstract: Novel compounds of the general structural formula I: ##STR1## have endothelin antagonist activity and are therefore useful in treating cardiovascular disorders, such as hypertension, pulmonary hypertension, postischemic renal failure, vasospasm, cerebral and cardiac ischemia, myocardial infarction, endotoxic shock, inflammatory diseases including Raynaud's disease and asthma.Type: GrantFiled: September 29, 1993Date of Patent: February 20, 1996Assignee: Merck & Co., Inc.Inventors: Ralph A. Rivero, Peter D. Williams, Daniel F. Veber
-
Patent number: 5457177Abstract: The radioligands are six amino acid peptides having iodinated tyrosine at amino acid position six, including Ala-pFPhe-hArg-Cha-hArg-Tyr(I)-NH.sub.2, which mimic the activated form of the thrombin receptor protein. Thrombin receptor radioligands of the present invention are useful for screening for thrombin receptor antagonists.Type: GrantFiled: June 16, 1993Date of Patent: October 10, 1995Assignee: Merck & Co., Inc.Inventors: Daniel F. Veber, Ruth F. Nutt, Dong-mei Feng, Robert J. Gould, Thomas M. Connolly
-
Patent number: 5420133Abstract: Phenoxyphenylacetic acids and derivatives of general structural formula I ##STR1## have endothelin antagonist activity and are therefore useful in treating cardiovascular disorders, such as hypertension, postischemic renal failure, vasospasm, cerebral and cardiac ischemia, myocardial infarction, inflammatory diseases, Raynaud's disease, and endotoxic shock, and asthma.Type: GrantFiled: March 19, 1993Date of Patent: May 30, 1995Assignee: Merck & Co., Inc.Inventors: Daljit S. Dhanoa, Kenneth J. Fitch, Daniel F. Veber, Thomas F. Walsh, David L. Williams, Jr.